Research remains an essential part of cancer care. In this blog, we will provide information about recent updates or new approvals as it applies to breast cancer written by Dr. Sharon Wilks. Dr. Adrienne Waks, breast oncologist at the Dana Farber Cancer Institute, recently presented at the 21st Annual International Future in Breast Cancer East (July 2022). She discussed the …
Research remains an essential part of cancer care. In this blog, we will provide information about recent updates or new approvals as it applies to breast cancer written by Dr. Sharon Wilks. Of the lectures from the 21st Annual International Congress on the Future of Breast Cancer, East, back in July 2022, a wonderful lecture by Dr. Stephanie Wong, who …
Research remains an essential part of cancer care. In this blog, we will provide information about recent updates or new approvals as it applies to breast cancer written by Dr. Sharon Wilks. Long-term use of Aromatase Inhibitors (AI) for endocrine blockade for postmenopausal women with hormone receptor positive breast cancer has been a well-established treatment for several decades in the …
Research remains an essential part of cancer care. In this monthly blog, we will provide information about recent updates or new approvals as it applies to breast cancer written by Dr. Sharon Wilks. Though enormously practice changing, we still have unmet needs and research at NEXT Oncology is looking at better ways to improve immune recognition for better tumor response …
Research remains an essential part of cancer care. In this monthly blog, we will provide information about recent updates or new approvals as it applies to breast cancer written by Dr. Sharon Wilks. Hormone Positive Breast (HR+) cancer defined by biopsy results of having a breast cancer staining positive for either the Estrogen Receptor (ER) or Progesterone Receptor (PR), or …
Cancer patients and their caregivers often have questions when exploring treatment options, especially when it comes to early-stage clinical trials. The physicians and clinical investigators at NEXT Oncology have pulled together a list of frequently asked questions. In this blog, they answer the questions in a succinct manner, but encourage patients to have more in-depth conversations with their physicians when …
UPDATE – As of August 22, 2022 – The FDA has approved the use of Trastuzumab Deruxtecan for patients with low expressing HER2 Neu positive breast cancer survivors with recurrent, metastatic disease. It was previously only approved for patients with HER 2 Neu over/ High expressing (HER 2 Neu 3+ or FISH positive for HER 2 Neu) breast cancers. Due to …
Dr. Andrae Vandross, who leads NEXT – Austin, has always had an invested interest in science and research. NEXT Oncology provided him the opportunity to combine his inquisitive drive in the laboratory with his compassion in the clinic to help identify the next therapies to treat cancer patients. His highest priority in leading Phase I clinical trials is educating his …
Research remains an essential part of cancer care. In this monthly blog, we will provide information about recent updates or new approvals as it applies to breast cancer written by Dr. Sharon Wilks. In 2022, we have a new treatment available for men and women with a rare form of breast cancer, known as Triple Negative Breast Cancer (TNBC). This …
Dr. Sharon Wilks considers her ability to work in cancer care a gift from heaven. But for those who have worked beside her or who have been treated by her, they consider her to be the gift. It seems that even after more than three decades of research and clinical cancer care, Dr. Wilks still follows her heart and puts …
